Respiratory Syncytial Virus

Pharmacists should educate patients about managing respiratory syncytial virus and let them know they may soon be able to get vaccinated.

The updated recommendations during a surge in cases emphasize the need to enhance emergency readiness daily to not interrupt continuous care of children’s mental and physical well-being.

When mildly ill, individuals who reflect on the potential consequences of their behavior are less likely to go to holiday gatherings and events.

Respiratory syncytial virus- and rhinovirus-induced wheezing illnesses differ from each other at multiple levels.

Palivizumab is a humanized monoclonal antibody approved by the FDA to prevent serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children.

RSVpreF produced vaccine efficacy of 66.7% against respiratory syncytial virus-associated lower respiratory tract illness in older adults.

Interventions such as mask-wearing and social distancing have been found effective at limiting the spread of respiratory diseases.

Investigators find that despite the same quantity of respiratory syncytial virus and presentation, some of the samples demonstrated signs of greater damage to cells.

A session presenter at the ASCP 2022 Annual Meeting explained how the COVID-19 pandemic significantly magnified the importance of infection prevention and control practices in long-term care.

American Society of Consultant Pharmacists executive director and CEO explained how staffing struggles in long-term care facilities can be an opportunity for pharmacists to expand the ways they provide support beyond immunizations alone.

Infection with RSV can take a variety of forms, ranging from a mild upper respiratory tract infection to severe, life-threatening acute respiratory failure.

Pre-planned safety reviews performed for the duration of the study found that the investigational vaccine is well-tolerated with no safety concerns for both the vaccinated individuals and their newborns.

Researchers suggest that winter 2020 to 2021 public health interventions lowered natural immunity in children and put them at greater risk of respiratory infection after restrictions were lifted.

There is currently no approved RSV vaccine despite ongoing research efforts.

The TaqMan SARS-CoV-2, Flu A/B, RSV RT-PCR multiplex assay can differentiate between 3 different viral infections (including COVID-19), making it highly cost-effective.

The vaccine candidate is composed of 2 preF proteins selected to optimize protection against the RSV A and B strains.

Francesca Ceddia, MD, senior vice president of respiratory vaccines at Moderna, said the company is in early stages of development for a combined mRNA vaccine for influenza, COVID-19, and RSV.

Francesca Ceddia, MD, senior vice president of respiratory vaccines at Moderna, discussed how mRNA vaccines could change the treatment landscape for respiratory illnesses.

This is the first RSV vaccination candidate to show clinically meaningful and statistically significant efficacy in adults aged 60 years and older.

This month's Rx product news features empagliflozin, mitapivat, and RSVpreF.

The Labcorp Seasonal Respiratory Virus RT-PCR DTC Test is the first direct-to-consumer multi-analyte COVID-19 test to be authorized by FDA.

RSVpreF gets breakthrough designation for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age or older.

The decision is informed by the results of a phase 2b proof-of-concept study that assessed the immunogenicity and safety of the drug in healthy pregnant women and their infants.

RSV causes an estimated 14,000 deaths and 177,000 hospitalizations annually among US adults over 65 years of age.

The study aimed to examine the impact of masking and social distancing practices used to control the spread of COVID-19.